SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

Core Viewpoint - SAB Biotherapeutics is advancing its clinical-stage biopharmaceutical product, SAB-142, aimed at delaying the onset or progression of type 1 diabetes (T1D) and will present findings at the ADA 84th Scientific Sessions in June 2024 [1][2] Company Overview - SAB Biotherapeutics focuses on developing human immunoglobulins (IgGs) for treating immune and autoimmune disorders without relying on human donors or convalescent plasma [12] - The company's lead asset, SAB-142, is designed to modify the disease progression of T1D, potentially changing the treatment paradigm [12] Product Details - SAB-142 is a fully human alternative to rabbit anti-thymocyte globulin (ATG), which has shown efficacy in slowing disease progression in clinical trials for T1D [3][10] - The mechanism of action for SAB-142 involves targeting immune cells that destroy pancreatic beta cells, aiming to preserve insulin production [4] - Unlike rabbit ATG, SAB-142 is expected to minimize adverse immune reactions, allowing for safer and more consistent re-dosing [4] Clinical Development - Following FDA IND clearance in May 2024, the company is expanding its clinical program for SAB-142 [11] - The ADA 84th Scientific Sessions will feature a poster presentation on the assessment of tolerance and safety for SAB-142, highlighting its potential in diabetes treatment [2][9]